Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025.

Pigment cell & melanoma research·2026

Same author

Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma.

Pigment cell & melanoma research·2026

Same author

Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy-Treated Melanoma.

Cancer immunology research·2025

Same author

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models.

Nature communications·2025

Same author

SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target.

Cell death & disease·2025

Same author

Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma.

The Journal of clinical investigation·2025

Search research articles

Related Experiment Video

Updated: Sep 21, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Packing a Punch against PD-L1.

Claudia Capparelli^1,2, Andrew E Aplin^1,2

¹Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania.

Cancer Discovery

|June 2, 2022

Summary

This summary is machine-generated.

Small-molecule immune-checkpoint inhibitors offer a promising alternative to antibody-based cancer therapies, potentially reducing immune-related side effects. This approach aims to enhance current cancer treatment strategies.

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Sep 21, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Area of Science:

Oncology
Immunology
Pharmacology

Background:

Antibody-based immune checkpoint inhibitors have revolutionized cancer therapy.
These therapies can cause significant immune-related adverse effects, limiting their use.

Discussion:

Small-molecule immune-checkpoint inhibitors are emerging as a viable alternative to antibody therapies.
This new class of drugs may offer improved safety profiles and efficacy.

Key Insights:

Small molecules provide a different mechanism for targeting immune checkpoints compared to antibodies.
Development of small-molecule inhibitors could overcome limitations of current antibody treatments.

Outlook:

Further research into small-molecule immune-checkpoint inhibitors is crucial for advancing cancer treatment.
These agents hold potential for broader application and improved patient outcomes in oncology.